Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0278883 (
metastatic melanoma
)
6,224
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The identification of cancer-associated long noncoding RNAs (lncRNAs) and the investigation of their molecular and biological functions are important to understand the molecular biology of cancer and its progression. Although the functions of lncRNAs and the mechanisms regulating their expression are largely unknown, recent studies are beginning to unravel their importance in human health and disease. Here, we report that a number of lncRNAs are differentially expressed in melanoma cell lines in comparison to melanocytes and keratinocyte controls. One of these lncRNAs,
SPRY4
-IT1 (GenBank accession ID AK024556), is derived from an intron of the
SPRY4
gene and is predicted to contain several long hairpins in its secondary structure. RNA-FISH analysis showed that
SPRY4
-IT1 is predominantly localized in the cytoplasm of melanoma cells, and
SPRY4
-IT1 RNAi knockdown results in defects in cell growth, differentiation, and higher rates of apoptosis in melanoma cell lines. Differential expression of both
SPRY4
and
SPRY4
-IT1 was also detected in vivo, in 30 distinct patient samples, classified as primary in situ, regional metastatic, distant metastatic, and nodal
metastatic melanoma
. The elevated expression of
SPRY4
-IT1 in melanoma cells compared to melanocytes, its accumulation in cell cytoplasm, and effects on cell dynamics, including increased rate of wound closure on
SPRY4
-IT1 overexpression, suggest that the higher expression of
SPRY4
-IT1 may have an important role in the molecular etiology of human melanoma.
...
PMID:The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. 2155 91
Metastatic melanoma
is the deadliest of all skin cancers. Despite progress in diagnostics and treatment of melanoma, the prognosis for metastatic patients remains poor. We previously showed that Membrane-type 1 Matrix Metalloproteinase (MT1-MMP) is one of the drivers of melanoma metastasis. Classically, MT1-MMP regulates a verity of cellular functions including cell-to-cell interaction and cell-to-matrix communication. Recently, MT1-MMP has been found to also modulate gene expression. To specifically assess MT1-MMP dependent gene regulation in melanoma, microarray gene expression analysis was performed in a melanoma cell line whose metastatic properties depend on the activity of MT1-MMP. We identified the tumor suppressor gene
SPRY4
as a new transcriptional target of MT1-MMP that is negatively regulated by the protease. Knockdown of MT1-MMP enhances
SPRY4
expression at the mRNA and protein level.
SPRY4
expression inversely correlates with that of MT1-MMP in melanoma samples and importantly, correlates with melanoma patient survival.
SPRY4
modulates MT1-MMP dependent cell migration such that inhibition of
SPRY4
rescues cell migration that has been impaired by MT1-MMP knock down. MT1-MMP decreases
SPRY4
in part through an MMP2/RAC1 axis we previously show promotes cell motility downstream of MT1-MMP. These results identify the tumor suppressor
SPRY4
as a novel molecular effector of MT1-MMP affecting melanoma cell motility.
...
PMID:MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility. 2639 17